Latest Medicine stories from Life.
A recent analysis highlights a troubling increase in drug shortages and pricing pressures in Europe, with U.S. authorities intensifying their scrutiny.
As the U.S. observes the situation, European countries are developing varied approaches to drug pricing, which could have significant implications for the pharmaceutical sector and patient access.
A recent report highlights a concerning trend in Europe, where cartels are increasingly recruiting young individuals for the trafficking of synthetic opioids, reflecting a shift in the illicit drug market.
In a significant drug bust, Chile has uncovered 1,080 tons of wood containing illegal substances, primarily cocaine and ketamine, intended for Europe.
Novo Nordisk expresses disappointment with a drug it previously contested with Pfizer. Meanwhile, Revolution and Tango show encouraging cancer results, and Incyte acquires a bleeding disorder treatment.
Lilly has released additional data regarding the safety and tolerability of its obesity drug retatrutide, contributing to ongoing discussions in the pharmaceutical sector.
As Spain's life expectancy rises, the country is increasingly turning to preventive and longevity medicine, aiming to make these treatments accessible and trustworthy for all.
A newly developed drug appears to offer a significant breakthrough in the treatment of hepatitis B, potentially leading to the elimination of the virus in many cases.
Recent findings suggest that while Boehringer Ingelheim’s obesity drug may effectively reduce liver fat, its overall weight loss results are less compelling.
Australia is moving towards implementing the world's first roadside limit for cannabis use, potentially allowing some drivers to pass drug tests that previously jeopardized their licenses.
The American Diabetes Association's annual conference in New Orleans showcased new insights, including developments in hormone receptors and a monthly obesity drug.
Recent findings from a midstage study indicate that Pfizer's obesity treatment, obtained from Metsera, may be effective with monthly dosing.
The recent cancellation of medical entrance tests affecting over 2 million candidates has ignited frustration towards Prime Minister Narendra Modi's administration.
RevMed's cancer treatment appears inaccessible for certain patients, while the Supreme Court maintains an essential pathway for generic drugs amid ongoing biotech developments.
Roche has leveled serious accusations against the U.S., claiming 'blackmail' tactics amid ongoing controversies surrounding drug reviews and skinny labels.
As we reflect on the six-year mark since the onset of the COVID-19 pandemic, experts are evaluating how coordinated responses to domestic violence have evolved during this challenging period.
The Department of Health and Human Services has announced that Americans at high risk of Ebola exposure during the ongoing outbreak in Central Africa will be able to receive an experimental antibody treatment.
A recent presentation on Revolution Medicines' pancreatic cancer drug garnered significant attention, earning a standing ovation. However, the broader biotech sector faced challenges this week.
Despite not yet receiving approval, Revolution Medicines' pancreatic cancer drug is already the subject of discussions regarding its potential expanded applications.
NewLimit, a longevity-focused startup, has successfully raised $435 million in funding, which will support its first clinical trial targeting liver medicine.